A variety of in vivo and more recently in vitro assays have been described to assess cell mediated immunity (CMI). Two methods routinely employed in our laboratory to assess CMI following exposure to chemicals in rodents include delayed hypersensitivity and in vitro lymphoproliferation. Preliminary studies indicate that depressed delayed hypersensitivity responses, as performed by a radiometric assay, correlates with altered susceptibility to infectious agents and tumor cell challenge following exposure to immunotoxic chemicals.
Introduction
Reports indicating that exposure to various environmental pollutants leads to immunological alterations in laboratory animals and even man has raised concerns regarding sensitive methodology for routine assessment of immunotoxicity (1, 2) . One concern in assay battery development is the use of appropriate models to examine cell-mediated immunity (CMI). In recent years, large numbers of in vivo and more recently in vitro assays have been developed to assess CMI. To insure accurate evaluation an in vivo assay, which represents a holistic approach, and a more defined in vitro assay, for CMI should be employed. Routinely, CMI is assessed in our laboratory by quantitating in vivo delayed hypersensitivity responses using a radiometric technique and in vitro lymphoproliferative responses following chemical exposure (3) . These techniques and their relationship to other aspects of immunity (i.e., host susceptibility, humoral immunity and the reticuloendothelial system) are examined. Considerations in selecting appropriate CMI assays include sensitivity, simplicity and extrapolation of dose-response curves from effect to no-effect levels as well as from rodent model systems to humans.
Assays for Cell-Mediated Immunity
CMI is evoked by T-lymphocytes, although macrophages and to a lesser extent polymorphonuclear leukocytes (PMNs) play an active role in these reactions (4) . CMI is responsible for classical delayed hypersensitivity reactions (DHRs), rejec- There are also a number of in vitro techniques that specifically assess macrophage and PMN functions. Those assays routinely employed in our laboratory include chemotaxis, phagocytosis, cytostasis, and chemiluminescence (8) release of lymphokines and/or development of specific cytotoxicity without the participation of antibody (9) . Locally it is manifested by cellular infiltration at the site of antigen administration. In humans, DHRs are measured by the intradermal administration of a panel of antigens to which previous exposure is likely (10 (12, 13) . We routinely employ a modification (3) of a radiometric ear assay originally described by Lefford (13) . This method, as performed in our laboratory, is depicted in Figure   1 . Administration of tritiated thymidine (3H-TdR) prior to antigenic challenge radiolabels monocyte precursors in the bone marrow. The response is presumably represented by mononuclear infiltration around the reaction site.
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In Table 2 Table 2 are considered under the influence of CMI and are discussed in detail elsewhere (14) . Although preliminary, the data in Table 2 
Lymphoproliferative Responses
Lymphoproliferative (LP) responses are a widely used correlate of CMI and can be defective in the absence of lymphopenia. In the microculture LP assay, general mitogens (e.g., plant lectins, bacterial products), specific antigens or alloantigens (i.e., mixed lymphocytes) are used to stimulate selectively the cell proliferation of splenic or peripheral lymphocytes (6) . Proliferation is measured by 3H-TdR incorporation into DNA, represented as CPM. Unlike specific antigens, mitogens are polyclonal activators some of which are capable of tions (see Table 3 ). In mice, phytohemagglutinin (PHA) and concanavalin A (Con A) are often used to activate T-lymphocytes, while lipopolysaccharide (LPS), isolated from gram-negative bacteria, is used to transform B-lymphocytes (3). Depressed LP responses occur in humans with inherited immunodeficiency (primary) diseases as well as various pathological or physiological conditions, including malignancies (Hodgkin's disease, lung cancer), intestinal lymphangiectasia, aging, chronic lymphatic leukemia, nutritional deprivation and in severe stress (e.g., post-surgery) (6, 17) .
Depressed LP response in experimental animals with normal numbers of lymphocytes has usually been interpreted as failure of cell activation. Recent studies have indicated that this may occur through tolerance or suppressor substances produced by regulatory subpopulations of macrophages and T-lymphocytes (6, 7). Other factors, however, 13 1 13 t 'TCDD was administered in mice pre/postnatally (via maternal exposure) as described previously (18) . PBB was given chronically (19) . All other chemicals were administered as described in Table 2. bCode:. = no effect; 4 = slight to moderate; 44 = marked effect: ND = not done.
should be considered as possibly causing depression of LP responses. Some of these factors include: a chemically induced lymphocytotoxicity as may occur with TCDD (1) (20) . In these studies, mice with depressed LP responses following exposure to TCPP or PBB also revealed decreased hematopoietic stem cell proliferation using in vitro spleen and bone marrow colony forming assays. Since these chemicals are biologically active, probably capable of binding to DNA, it would be expected that the more proliferative cell populations (i.e., stem and lymphoid cells) would have a greater predilection to chemical injury. Benzo(a)pyrene appeared selectively to affect B-lymphocytes while sparing CMI, although T-cell LP responses were somewhat affected. This is not a unique phenomenon in immunotoxicology, since exposure to heavy metals under many circumstances induces similar effects (21) .
In summary, many assays are available to assess CMI following chemical exposure. Since, in general, these assays represent "biological phenomena" one should employ both in vivo and in vitro assays for proper assessment. Assay selection should be based upon sensitivity, simplicity and extrapolation of dose response curves from effect to noeffect levels as well as from rodent systems to humans. Preliminary studies reported here, which should be interpreted with caution, suggest that a depressed DHR corresponds with increased host susceptibility. On the other hand, while marked suppression of T-cell LP responses correlates with suppressed DHRs, less severe depression does not correlate with other immune or host resistance parameters, but rather may be an early indicator of general toxicity.
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